08.07.2020 15:04:45

Pre-market Movers In Healthcare Sector: NNVC, BCRX, XENT, VVUS…

(RTTNews) - What's moving these stocks in the pre-market hours today?

In The Green

1. Shares of NanoViricides Inc. (NNVC) are up over 50% at $10.47 in pre-market trading on Wednesday, following news that three of its anti-coronavirus drug candidates demonstrated excellent safety and tolerability in groups of mice. Previously, these drug candidates had shown strong effectiveness in a lethal lung infection model in rats using hCoV-NL63, a coronavirus that uses the same ACE2 receptor as SARS-CoV-2 which causes COVID-19.

The promising data clear the path for further development towards a treatment for SARS-CoV-2, noted the Company.

2. Shares of Intersect ENT Inc. (XENT) are up more than 35% at $18.76 in pre-market trading today, on no news. Intersect ENT is a company focused on developing therapies/products for patients with ear, nose, and throat conditions. The Company is slated to report second-quarter financial results in the last week of July. In the first quarter of 2020, revenue was $19.8 million compared to $26.7 million in the first quarter of 2019.

3. VBI Vaccines Inc. (VBIV) is up over 26% at $4.26 in pre-market trade on no news. VBI Vaccines is a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines. The Company's lead drug candidate is Sci-B-Vac, a tri-antigenic Prophylactic Hepatitis B (HBV) Vaccine, for which positive topline results were reported from a second pivotal Phase 3 study, dubbed CONSTANT, in January of this year.

The Company plans to make regulatory filings for Sci-B-Vac in the U.S., Europe, and Canada, beginning in Q4, 2020. A pan-coronavirus vaccine candidate targeting COVID-19, SARS, and MERS is also being evaluated by the Company, with the goal of having clinical study material available in Q4 2020.

4. BioCryst Pharmaceuticals Inc. (BCRX) is up more than 8% at $5.85 in pre-market trading. The Company's coronavirus antiviral program Galidesivir (BCX4430) is under a phase I study in subjects with Yellow Fever or COVID-19 in Brazil.

5. GenMark Diagnostics Inc. (GNMK) is up over 7% at $16.80 in pre-market trading today. The Company expects total revenue for the second quarter of 2020 to be approximately $40.1 million, representing an increase of 118% over the second quarter of 2019, and well above the analysts' consensus revenue estimate of $31.39 million. The Q2 financial results are expected to be reported by early August.

In the Red

1. VIVUS Inc. (VVUS) is down more than 33% at $0.54 in pre-market trading today. The Company has completed the solicitation of an in-court prepackaged plan of reorganization, under which IEH Biopharma LLC will take 100% ownership of VIVUS, ahead of its July 7, 2020 chapter 11 filing.

2. Annovis Bio Inc. (ANVS) is down 8.36% at $6.25 in pre-market trading today. After having gained more than 76% yesterday, following an update related to its lead compound ANVS401, the stock is giving back some of its gains.

Nachrichten zu Intersect ENT Incmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Intersect ENT Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Annovis Bio Inc Registered Shs Accred Inv 5,33 -5,83% Annovis Bio Inc Registered Shs Accred Inv
BioCryst Pharmaceuticals 7,24 -3,70% BioCryst Pharmaceuticals